Short Interest in iBio, Inc. (NYSEAMERICAN:IBIO) Decreases By 15.5%

iBio, Inc. (NYSEAMERICAN:IBIO) was the recipient of a significant drop in short interest during the month of October. As of October 31st, there was short interest totalling 260,100 shares, a drop of 15.5% from the October 15th total of 307,800 shares. Currently, 2.9% of the shares of the company are sold short. Based on an average daily volume of 121,300 shares, the short-interest ratio is presently 2.1 days.

iBio Stock Up 6.0 %

NYSEAMERICAN:IBIO traded up $0.13 during trading hours on Friday, reaching $2.28. The company had a trading volume of 107,066 shares, compared to its average volume of 1,178,068. iBio has a 1-year low of $1.02 and a 1-year high of $6.12. The company has a debt-to-equity ratio of 0.04, a current ratio of 0.91 and a quick ratio of 0.91.

iBio Company Profile

iBio, Inc, a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company’s technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein.